Finley John David 4
4 · PALISADE BIO, INC. · Filed Jul 8, 2026
Research Summary
AI-generated summary of this filing
PALISADE BIO (PALI) CEO John D. Finley Sells Shares
What Happened
Finley John David (CEO, CFO & Director) reported the settlement/vesting of 335,167 restricted stock units (RSUs) on July 6, 2026, which converted into common shares. To cover tax withholding tied to that RSU vesting, he sold 146,798 shares in the open market on July 7, 2026 for total proceeds of $303,343 (weighted average ≈ $2.07). He also exercised derivative warrants/options for 133 shares on July 7, 2026 by paying $0.70 per share ($93).
Key Details
- Primary transactions: RSU settlement (335,167 shares vested/converted on 2026-07-06) and open-market sale of 146,798 shares on 2026-07-07 for $303,343.
- Sale price: reported as $2.07 (weighted average); actual sale prices ranged $2.045–$2.09 per share (see footnote).
- Small exercise: 133 shares exercised at $0.70 each (total $93) on 2026-07-07.
- Purpose of sale: shares sold to cover tax withholding obligations related to RSU vesting (footnote F3).
- Footnotes of note: F1 = RSUs settled from Feb 9, 2026 grant; F7 = RSU vesting schedule (1/6th on July 6, 2026, then quarterly); F4 = weighted-average sale price disclosure; F2/F10 provide background on other holdings/warrants.
- Filing timing: Form 4 filed July 8, 2026 for transactions on July 6–7, 2026 (timely based on the report).
- Shares owned after transaction: not specified in the excerpt provided in this summary.
Context
This activity is largely administrative: the large share increase came from RSU settlement (an award converting to stock) and the subsequent sale was to satisfy tax withholding—common practice and not necessarily a directional insider buy/sell signal. The small 133-share exercise appears to be a warrant/option exercise (cash paid $93). Derivative entries reporting a $0 disposition reflect conversion/settlement mechanics rather than cash sales.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1][F2]2026-07-06+335,167→ 364,353 total - Sale
Common Stock
[F3][F4]2026-07-07$2.07/sh−146,798$303,343→ 217,555 total - Exercise/Conversion
Common Stock
2026-07-07$0.70/sh+133$93→ 217,688 total - Exercise/Conversion
Restricted Stock Units
[F6][F7]2026-07-06−335,167→ 1,675,833 total→ Common Stock (335,167 underlying) - Exercise/Conversion
Series 2 Common Stock Purchase Warrant
[F8][F9][F10]2026-07-07−133→ 0 totalExercise: $0.70Exp: 2027-08-16→ Common Stock (133 underlying)
- 51(indirect: By LLC)
Common Stock
[F5]
Footnotes (10)
- [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 9, 2026.
- [F10]Represents Series 2 Common Stock Purchase Warrants received as part of the Units purchased by Reporting Person. The Series 2 Warrants became exercisable upon receipt of stockholder approval per Nasdaq rules, which was obtained on October 6, 2022.
- [F2]Includes 1,899 shares acquired under the Issuer's Employee Stock Purchase Plan on May 20, 2026. In addition, the amount of securities beneficially owned was reduced by 66 shares due to an administrative error in the total reported in the Form 4 filed February 13, 2026.
- [F3]The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.045 to $2.09, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The Reporting Person is the managing member of FCW Investments, LLC and has the sole investment and voting power over the securities held by this entity.
- [F6]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F7]The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
- [F8]As adjusted in accordance with the terms of the Series 2 Common Stock Purchase Warrants following the public offering that closed on October 2, 2025.
- [F9]Reflects adjustments pursuant to the Issuer's 1-for-50 reverse stock split effective November 15, 2022, and the Issuer's 1-for-15 reverse stock split effective April 5, 2024.